DarioHealth (DRIO) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
16 Apr, 2026Platform overview and market opportunity
AI-powered, multi-condition platform addresses cardiometabolic, behavioral, and musculoskeletal care, supporting up to 6+ conditions with bundled pricing at $74 per engaged member per month.
Serviceable addressable market estimated at over $250 billion, with rapid expansion enabled by platform architecture.
76% of U.S. adults have a chronic disease, and 51% have two or more comorbid conditions, highlighting significant demand.
Blue-chip client base includes 160+ clients, such as Fortune 100 employers and national health plans.
Channel partnerships provide access to approximately 116 million covered lives, accelerating market penetration.
Product features and engagement
Integrated digital platform combines connected devices, AI-powered coaching, community support, and clinical services for personalized care.
Comprehensive support for diabetes, hypertension, weight management, musculoskeletal, behavioral health, and GLP-1 management.
Average member retention rate after 12 months is 75%, with members using an average of 2.4 solutions.
Proprietary AI model achieves 90% accuracy in predicting blood sugar fluctuations and delivers a 20% increase in engagement for hypertension management.
100+ published peer-reviewed studies validate clinical outcomes and ROI.
Financial performance and growth
FY2025 revenue reached $22.4M, with Q4 resuming sequential growth and a 10% organic YoY increase.
Non-GAAP gross margin for B2B2C business is approximately 80%, with a 28% YoY reduction in GAAP OpEx.
$12.9M in new and soon-to-be-closed ARR contracts, contributing to 2026-2027 growth.
$122M pipeline of commercial opportunities, with 70% focused on multi-condition contracts.
Targeting cashflow breakeven by mid-2027, with a 30% decrease in non-GAAP operating loss expected in 2026.
Latest events from DarioHealth
- Multi-condition care and provider expansion underpin $13.1M in ARR opportunities.DRIO
Investor presentation - Multi-condition care and AI underpin expansion, 80% non-GAAP B2B2C gross margin, and ARR growth.DRIO
Corporate presentation - Q3 revenue rose 6.1%; ARR supports 2027 growth expectations amid funding risks.DRIO
Q3 2026 - Gross margin rose to 62% and net loss improved 39% as ARR, cash, and commercial wins increased.DRIO
Q2 2026 - AI-driven multi-condition platform delivers clinical results, high retention, and rapid growth.DRIO
Corporate presentation - Q1 2026 revenue rose to $5.6M, costs fell, but liquidity concerns remain despite strong pipeline.DRIO
Q1 2026 - AI-driven, multi-condition platform achieves clinical validation, strong growth, and high client retention.DRIO
Corporate presentation - Registering up to $100M in securities to support growth and innovation in digital health.DRIO
Registration filing - Record new business and margin gains set the stage for accelerated, ARR-driven growth by 2027.DRIO
Q4 2025